Document is current

Article History

Accepted: 4 October 2021

First Online: 18 October 2021

Declarations

:

: The ESME AMLC database receives financial support from an industrial consortium (AstraZeneca, MSD, BMS, Janssen, Amgen, and Roche). Data collection, analysis, and publication are fully managed by Unicancer independently of the industrial consortium.

: CC: Grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi, BMS, MSD, Lilly, Novartis, Takeda, Bayer, and Amgen. TF received fees from Cellectis that were compensated by his institution. DD: No conflict of interest. MP: Grants, personal fees, and non-financial support from AstraZeneca, Roche, Boehringer Ingelheim, and Takeda, outside the submitted work. NG: Research/grant support from MS, AstraZeneca, AbbVie, Amgen, Boehringer-Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sivan, and Trizell and consultative services for BMS, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, and Sivan. ED: No conflict of interest. HL: Consulting fees from BMS, AstraZeneca, Takeda, Roche, Pfizer, Novartis, and Lilly. JO: No conflict of interest. DP: Consulting, advisory role or lectures for AstraZeneca, AbbVie, Bristol-Myers Squibb, Celgene, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung, and Janssen; travel, accommodation, and expenses for meetings for AstraZeneca, Roche, Novartis, prIME Oncology, and Pfizer; and advisory role for AstraZeneca, AbbVie, Bristol-Myers Squibb, Celgene, Merck, Novartis, Pfizer, Roche, Samsung, and Janssen. CK: No conflict of interest. SH: Fees from Takeda and AstraZeneca to participate in review activities. EP: Consulting fees from Roche, Astra Zeneca, BMS, MSD, and Takeda and support for meetings from Takeda and MSD. CCD: No conflict of interest. GC: No conflict of interest. GS: No conflict of interest. LB: No conflict of interest. XQ: No conflict of interest. RG, SC, RS, AM, and PDL did not report conflicts of interest.

: Unicancer manages the ESME AMLC data platform in accordance with current best practice guidelines. In compliance with French regulations, the ESME data platform was authorized by the French data protection authority (initial authorization no. DE-2017-397 and subsequent amendment dated October 14, 2019 in accordance with General Data Protection Regulation). Data are updated on a yearly basis and run into a data-management process aimed at ensuring the quality of the data analyzed.

: Not applicable.

: Individual participant data that underlie the reported results will not be made available.

: Conceptualization: CC, TF, DD, and XQ. Formal analysis: GC. Methodology: CC, TF, DD, GS, LB, and XQ. Project administration: GS and LB. Resources: GS and LB. Software: GC. Supervision: CC, TF, DD, and XQ. Validation: GS and LB. Visualization: GC. Writing—original draft: CC and LB. Writing—review and editing: TF, DD, MP, NG, ED, HL, RG, SC, JO, RS, DP, AM, CK, PDL, SH, EP, CCD, LB, and XQ.